• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

15.53 +0.69 (+4.65%)
Streaming Delayed Price Updated: 3:34 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aardvark Therapeutics, Inc. - Common Stock

News headline image
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
November 25, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
November 13, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 11, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
November 04, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 03, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
November 03, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
October 22, 2025
Aardvark to host Investor Webinar with members of the management team, leading key opinion leaders and patient advocates on November 5, 2025 
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
October 08, 2025
Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient Population 
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 23, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 04, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
August 27, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
August 13, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
August 12, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
July 18, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
June 24, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
May 19, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 14, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
May 07, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
March 31, 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap